News of the WeekClinical Trials

Halt of Celebrex Study Threatens Drug's Future, Other Trials

See allHide authors and affiliations

Science  24 Dec 2004:
Vol. 306, Issue 5705, pp. 2170
DOI: 10.1126/science.306.5705.2170a

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Summary

New research indicates Pfizer's COX-2 inhibitor Celebrex may cause increased risk of heart attacks and strokes, leading to the halting of some clinical trials involving the drug. Dozens of other COX-2 inhibitor trials are undergoing careful review. The scenario is strikingly similar to what happened this fall to Merck's COX-2 inhibitor Vioxx, which the Food and Drug Administration subsequently removed from the market.